Numinus Wellness

Numinus Wellness Inc. (OTCQX:NUMIF), a leader in psychedelic-assisted mental health care, has announced a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November...

The U.S. Food and Drug Administration (FDA) has issued a complete response letter for MDMA-assisted psychotherapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) in which it calls for an additional phase 3 trial to further evaluate its safety and efficacy. As Psychiatric Times...

Numinus Wellness Inc. (OTCQX: NUMIF) announced the launch of its new clinical program, ketamine for chronic and serious medical illness, to be first introduced at Utah, BC and Quebec clinics and then expanded to Numinus' remaining facilities. The company’s model includes...

Plant-based wellness product provider HempLucid is advancing medically supervised ketamine-assisted therapy (KAP) as an employee healthcare benefit. The new move does make sense, considering the company’s mission being “to create innovative products that inspire others to become...

Novamind (OTCQB: NVMDF), which is to be acquired by Numinus Wellness (OTCMKTS: NUMIF), recently announced a collaboration with health coaching platform HealCommunity. The collaboration with HealCommunity will help expand the recently announced Groups by Novamind project, by providing remote group...

This article by Sarah Abelsohn was originally published on Psychedelic Spotlight, and appears here with permission. In this episode James, from The Psychedelic Investor, sits down with Numinus Wellness’ (OTC: NUMIF, TSX.V: NUMI) CEO Payton Nyquvest for the Psychedelic Spotlight Podcast...

Numinus Wellness (Pink: LKYSF) (TSXV: NUMI) announced the launch of a new clinical trial that will add information to an industry insider debate: is naturally produced psilocybin as good as synthetic psilocybin? Numinus’ new Phase I clinical trial, to be conducted in partnership...

Mind Cure Closes $18M Raise Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering. The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0.60 per unit.  The proceeds...

Health Canada Considers MDMA And Psilocybin 'Special Access' Program This week, Health Canada opened a public consultation on its “proposal to restore potential access to restricted drugs through the Special Access Program (SAP).” The SAP allows healthcare professionals to...

Numinus and MAPS Collaborate to Study MDMA in Canada Numinus Wellness (TSXV: NUMI) and the MAPS Public Benefit Corporation have joined forces to bring MDMA-assisted psychotherapy through clinical trials for approval in Canada. The pair will first seek permission to perform a single-arm, open-label...

Cybin Raises CA$45 Million and Heads Towards NEO Exchange This week, Toronto-based Cybin Corp. announced the closing of a private offering for CA$45 million ($34.2 million). The raise was completed in connection to Cybin’s previously-announced reverse take-over with Clarmin Explorations (TSXV...

Here comes another Friday, with the latest updates on leadership changes within the cannabis industry. Heritage Cannabis Expands Leadership Team Heritage Cannabis Holdings Corp. has tapped Umar Syed to serve as its president, U.S. & International medical products. Syed brings over two...